journal of Internal Medicine 1 9 9 1 : 230: 511-517
Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension T. FORSLUND*t. P. FRANZEN*, & R. BACKMAN* From the *Department of Internal Medicine, Mjolbolsta Hospital, Mjdlbolsta, and the Foundation Institute for Medical Research, Helsinki, Finland
t Minerva
Abstract. Forslund T, Franzen P, Backman K (Department of Internal Medicine, Mjolbolsta Hospital, Mjolbolsta. and the Minerva Foundation Institute for Medical Research, Helsinki, Finland). Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension. journal of Internal Medicine 1 9 9 1 : 230: 5 1 1-51 7. Seventeen patients with mild to moderate hypertension, as indicated by a diastolic blood pressure (DPB) of 95-115 mmHg (WHO I), were treated in a randomized, double-blind, parallel study, with either 5 mg of fosinopril, a new phosphinic acid-containing angiotensin converting enzyme (ACE) inhibitor, or 2 5 mg of hydrochlorothiazide administered orally once daily for 4 weeks after a 4- to 6-week run-in period of placebo. The doses were increased to 10 mg of fosinopril or 50 mg of hydrochlorothiazide if DBP remained above 9 5 mmHg. The blood pressure (BP) fell from 1 5 7 f 1 2 / 1 0 4 + 7 mmHg (mean valuefSD) at the start of the study to 1 4 6 + 2 1 / 9 7 f 8 mmHg ( P < 0.02) after 4 weeks, and to 1 4 9 f 1 9 / 9 7 f 7 mmHg ( P
Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension T. FORSLUND*t. P. FRANZEN*, & R. BACKMAN* From the *Department of Internal Medicine, Mjolbolsta Hospital, Mjdlbolsta, and the Foundation Institute for Medical Research, Helsinki, Finland
t Minerva
Abstract. Forslund T, Franzen P, Backman K (Department of Internal Medicine, Mjolbolsta Hospital, Mjolbolsta. and the Minerva Foundation Institute for Medical Research, Helsinki, Finland). Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension. journal of Internal Medicine 1 9 9 1 : 230: 5 1 1-51 7. Seventeen patients with mild to moderate hypertension, as indicated by a diastolic blood pressure (DPB) of 95-115 mmHg (WHO I), were treated in a randomized, double-blind, parallel study, with either 5 mg of fosinopril, a new phosphinic acid-containing angiotensin converting enzyme (ACE) inhibitor, or 2 5 mg of hydrochlorothiazide administered orally once daily for 4 weeks after a 4- to 6-week run-in period of placebo. The doses were increased to 10 mg of fosinopril or 50 mg of hydrochlorothiazide if DBP remained above 9 5 mmHg. The blood pressure (BP) fell from 1 5 7 f 1 2 / 1 0 4 + 7 mmHg (mean valuefSD) at the start of the study to 1 4 6 + 2 1 / 9 7 f 8 mmHg ( P < 0.02) after 4 weeks, and to 1 4 9 f 1 9 / 9 7 f 7 mmHg ( P
